Provided by Tiger Fintech (Singapore) Pte. Ltd.

Aura Biosciences, Inc.

5.47
-0.4500-7.60%
Post-market: 5.470.00000.00%16:37 EDT
Volume:293.55K
Turnover:1.65M
Market Cap:274.73M
PE:-3.12
High:6.00
Open:5.86
Low:5.46
Close:5.92
Loading ...

Company Profile

Company Name:
Aura Biosciences, Inc.
Exchange:
NASDAQ
Establishment Date:
2009
Employees:
108
Office Location:
80 Guest Street,5th Floor,Boston,Massachusetts,United States
Zip Code:
02135
Fax:
- -
Introduction:
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmette–guérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Directors

Name
Position
David Johnson
Chairman and Director
Elisabet de los Pinos
Chief Executive Officer and Director
Antony Mattessich
Director
Giovanni Mariggi
Director
Karan Takhar
Director
Raj Parekh
Director
Sapna Srivastava
Director

Shareholders

Name
Position
Elisabet de los Pinos
Chief Executive Officer and Director
Mark De Rosch
Chief Operating Officer
Julie Feder
Chief Financial Officer
Cadmus Rich
Chief Medical Officer and Head of Research and Development
Christopher Primiano
Chief Business Officer